Emibetuzumab

Emibetuzumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction, leading to MET internalization and degradation.

Clinical Use

A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.

Emibetuzumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Emibetuzumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Aladdin Scientific	+1-+1(833)-552-7181	sales@aladdinsci.com	United States	57511	58
ShangHai Biochempartner Co.,Ltd	17754423994 17754423994	2853530910@QQ.com	China	8011	62
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1565	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10333	58
AntibodySystem	17762345272 18162686757	biolab-reagents@atagenix.com	China	9819	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 13720134139	orders@jknbiochem.com	China	5388	58
Shanghai Aladdin Biochemical Technology Co.,Ltd.	+86-18521732826	market@aladdin-e.com	China	48466	58
Changsha Fuzhen Biotechnology Co.，LTD	0731-18670069 18670069958	184792226@qq.com	China	3194	58
TargetMol Chemicals Inc.	15002134094	marketing@targetmol.cn	China	28091	58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd	17316404525	209533805@qq.com	China	9652	58

---

• Emibetuzumab
• Research Grade Emibetuzumab(DHC34201)
• Emibetuzumab (anti-MET)
• LY2875358
• 1365287-97-3